Health Canada approves Ryaltris for treatment of Seasonal Allergic Rhinitis
Ryaltris is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Ryaltris
Glenmark and Lotus enter into partnership for Ryaltris in key South East Asian markets
Glenmark will be responsible for the manufacturing and supply of Ryaltris, while Lotus International will be responsible for the…
Glenmark gets US FDA nod for nasal spray to treat seasonal allergic rhinitis
With this NDA approval, the company looks forward to bringing this new medicine to physicians and their patients for the treatment…
Glenmark receives marketing approval for its nasal spray in 13 countries across EU and UK
Glenmark has also partnered with Hikma Pharmaceuticals PLC and Bausch Health for the commercialisation of Ryaltris in the US and…
Glenmark’s Ryaltris nasal spray gets approval in Europe for treatment of allergic rhinitis
It is a novel fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for the treatment of symptoms…
Glenmark and Bausch Health join together to commercialise RYALTRIS nasal spray in Canada
Glenmark Pharmaceuticals and Bausch Health Companies have entered into an exclusive licensing agreement for the commercialisation…
Glenmark, Bausch Health partner to commercialise RYALTRIS nasal spray in Canada
RYALTRIS is currently under review by Health Canada with a proposed indication for the treatment of seasonal allergic rhinitis in…
Glenmark gets marketing approval for Ryaltris, single nasal spray in Russia
It is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age
Glenmark Pharma and Menarini enter into exclusive licensing agreement for commercialising Ryaltris…
Under the terms of the agreement, Glenmark will be responsible for the continued development and regulatory approval of Ryaltris…